La cadena de opciones muestra datos clave de las opciones de acciones de OptiNose a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para OptiNose..

OptiNose (NASDAQ:OPTN) Bolsa, Cadena de Opciones

OptiNose

OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Five,Below,Now,Open,-,Closeup,Of,Sign,On,Building

AGMH

AKBA

BHIL

DEVS

EFXT

FIVE

IOBT

MAZE

MHUA

OPTN

RVSB

VRPX

ZCAR

Las acciones de Five Below se disparan tras superar expectativas. Conoce otros grandes movimientos bursátiles en el premercado de EE.UU.

Las acciones de Five Below (FIVE) suben un 12%; Aquí están 20 acciones que se mueven en premercado

OptiNose Inc

China firmly rejected responsibility for the U.S. fentanyl crisis on Tuesday, calling Washington&#8217;s punitive tariffs unreasonable even as broader trade tensions between the world&#8217;s two largest economies show signs of easing.
What Happened: &#8220;The responsibility of tackling the fentanyl issue in the United States lies within the U.S. itself,&#8221; Chinese foreign ministry spokesperson Lin Jian stated during a regular press briefing, according to Reuters. Lin was responding to questions about whether fentanyl would be discussed in future trade negotiations.
The comments come just days after both nations pledged to significantly reduce tariffs following productive talks in Switzerland. Despite this progress, the U.S. maintained its 20% tariffs specifically tied to fentanyl, claiming Beijing hasn&#8217;t done enough to stem the flow of precursor chemicals used to manufacture the deadly opioid.
See Also: <a href="https://www.benzinga.com/markets/equities/25/05/45368550/apple-may-up-its-numbers-amid-china-tariff-truce-trump-talks-500-billion-us-investment-after-tim-cook-call">Apple May &#8216;Up Its Numbers&#8217; Amid China Tariff Truce: Trump Talks $500 Billion US Investment After Tim Cook Call</a>
Why It Matters: President Donald Trump&#8216;s Monday executive order decreased general <a href="https://www.benzinga.com/government/regulations/25/05/45368852/trump-lowers-de-minimis-tariff-on-chinese-imports-from-120-to-54-pauses-200-postal-fee-amid-90-day-trade-shift">Chinese import tariffs to 10% for a 90-day negotiation period</a> and reduced the de minimis rate on low-value imports from 120% to 54%, effective Tuesday. However, the fentanyl-related tariffs remained intact.
Analysts suggest the fentanyl issue could become a <a href="https://www.benzinga.com/news/global/25/05/45188171/china-pushes-for-special-envoys-as-direct-deal-with-trump-deemed-risky-plans-fentanyl-concessions-as-negotiating-leverage-report">strategic bargaining chip in upcoming negotiations</a>. &#8220;Beijing is hoping to use fentanyl cooperation as either a catalyst for U.S.-China trade talks or a bargaining chip in a future round of negotiations,&#8221; Jeremy Chan of Eurasia Group said.
Morgan Stanley economists project that continued negotiations could potentially lower overall tariffs on Chinese imports to 34% by the end of 2025, which would indicate the eventual elimination of the 20% fentanyl-specific tariff if sufficient progress is made on addressing U.S. concerns.
Image Via Shutterstock 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/restaurants/25/05/45369152/mcdonalds-launches-massive-summer-hiring-drive-for-375000-workers-amid-us-expansion-plans-and-slumping-sales">McDonald&#8217;s Launches Massive Summer Hiring Drive For 375,000 Workers Amid US Expansion Plans And Slumping Sales</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

News

Economics

China Rejects US Blame For Fentanyl Crisis, Calls Tariff Penalties Unreasonable Amid Easing Trade Tensions

Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) affirms FY2025 FFO guidance from $0.57-$0.61 to $0.57-$0.61 vs $0.54 analyst estimate. Affirms FY2025 sales outlook from $183.39 million-$188.17 million to $183.39 million-$188.17 million vs $186.60 million estimate.

Guidance

SOHO

Sotherly Hotels Affirms FY2025 FFO Guidance of $0.57-$0.61 vs $0.54 Est; Affirms FY2025 Sales Guidance of $183.39M-$188.17M vs $186.60M Est

The shares of Avic Chengdu Aircraft, known for manufacturing fighter jets like the JF-17 Thunder and the J-10C Vigorous Dragon, saw a 41.08% surge over the past five days since the commencement of the<a href="https://www.benzinga.com/news/global/25/05/45335338/trump-makes-india-pakistan-ceasefire-declaration-in-casual-manner-thank-you-for-your-attention-to-this-matter"> India-Pakistan conflict.</a>
What Happened: This rise was amid growing tensions between India and Pakistan following New Delhi&#8217;s recent military actions to avenge the alleged killings of tourists by <a href="https://www.benzinga.com/news/global/25/05/45369837/piers-morgan-tears-into-pakistani-expert-who-says-isi-didnt-know-osama-bin-laden-was-living-near-military-base-all-they-had-to-do-was-get-a-pair-of-binoculars">Pakistani terrorists</a> in Pahalgam, Kashmir.
On Friday, U.S. officials confirmed that a Chinese-made J-10 fighter jet fired air-to-air missiles at Indian aircraft, reportedly resulting in the downing of a French-built Rafale jet. The Pakistani Defense Minister, Khawaja Muhammad Asif, also said that the Chinese-made J-10 was used to shoot down three of India's newly acquired Rafale jets. 
Notably, the Indian military has not issued a clear response to the claim. "We are in a combat scenario and losses are a part of it. All our pilots are back home," stated Air Marshal A.K. Bharti on Sunday.
However, after a steep rise, the Avic Chengdu stock tumbled over 7% on Tuesday, possibly in response to a statement from Indian Prime Minister Narendra Modi. Modi on Monday announced the successful completion of Operation Sindoor. This statement triggered a massive selloff in Chinese defense stocks.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45354990/scottie-pippen-declares-altcoin-season-as-ethereum-xrp-dogecoin-shiba-inu-rally" target="_blank" rel="noreferrer noopener">Scottie Pippen Declares &#8216;Altcoin Season&#8217; As Ethereum, XRP, Dogecoin, Shiba Inu Rally &#8211; Benzinga</a>
Why It Matters: If confirmed, this would be the first combat success of the J-10 family since the original J-10 was unveiled 27 years ago. Pakistan, a long-standing ally of China, is the only foreign country operating the advanced J-10C, with a fleet of 20. This incident also marked the first reported loss of a Rafale fighter jet in combat, according <a href="https://www.scmp.com/news/china/military/article/3309781/j-10cs-deepseek-moment-beijing-muted-china-cheers-fighter-jet-combat-reports">to</a> the South China Morning Post.
While Chinese citizens praised the J-10C fighter jet&#8217;s role in the India-Pakistan conflict as a milestone for China&#8217;s defense industry, Beijing maintained a cautious stance. Analysts attributed this to geopolitical sensitivities and military prudence. The only official response from Beijing urged both countries to show restraint and avoid escalating tensions, reported the publication. 
Meanwhile, this incident had sent <a href="https://www.benzinga.com/25/05/45342121/chinese-made-pakistani-jet-downs-two-indian-aircraft">shockwaves across defense circles </a>and rattled investors, causing shares of French manufacturer Dassault Aviation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DUAVF#OTC">DUAVF</a>) to plunge.
President Donald Trump announced on Saturday a U.S.-<a href="https://www.benzinga.com/markets/equities/25/05/45336288/india-pakistan-ceasefire-teeters-as-blasts-shatter-calm-in-kashmir">brokered ceasefire </a>between India and Pakistan.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/05/45368511/china-to-us-goods-shipment-jump-after-90-day-tariff-postponement-a-big-backlog-is-looming" target="_blank" rel="noreferrer noopener">China To US Goods Shipment Jump After 90-Day Tariff Postponement: &#8216;A Big Backlog Is Looming&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

Markets

DUAVF

This Chinese Defense Stock Soared Over 41% In 5 Days: What's Going On?

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) affirms FY2025 sales outlook from $75.00 million-$90.00 million to $75.00 million-$90.00 million vs $82.49 million estimate.

YMAB

Y-mAbs Therapeutics Affirms FY2025 Sales Guidance of $75.00M-$90.00M vs $82.49M Est

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) sees Q2 sales of $17.000 million-$19.000 million vs $19.61 million analyst estimate.

Y-mAbs Therapeutics Sees Q2 Sales $17.000M-$19.000M vs $19.61M Est

Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.64 by 1.56 percent. This is a 1725 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $4.84 billion which missed the analyst consensus estimate of $4.89 billion by 1.03 percent. This is a 29.65 percent increase over sales of $3.73 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Sea Q1 EPS $0.65 Beats $0.64 Estimate, Sales $4.84B Miss $4.89B Estimate

Needham analyst Joseph Stringer maintains Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) with a Buy and lowers the price target from $16 to $11.

Price Target

Analyst Ratings

ANNX

Needham Maintains Buy on Annexon, Lowers Price Target to $11

Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.20) by 40 percent. This is a 20 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $20.90 million which beat the analyst consensus estimate of $19.61 million by 6.62 percent. This is a 4.88 percent increase over sales of $19.93 million the same period last year.

Y-mAbs Therapeutics Q1 EPS $(0.12) Beats $(0.20) Estimate, Sales $20.90M Beat $19.61M Estimate

Teleflex Reports Titan SGS Stapler Associated With Lower Post-Operative GERD Rates In 7-Year Retrospective Study Of Robotic Sleeve Gastrectomy Patients

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) today announced the appointment of Stephen J. Hemsley as its chief executive officer, effective immediately, following Andrew Witty's decision to step down as CEO for personal reasons. Hemsley, who served as company CEO from 2006-2017, will remain chairman of the company's Board of Directors and Witty will serve as a senior adviser to Hemsley.
Additionally, the company suspended its 2025 outlook as care activity continued to accelerate while also broadening to more types of benefit offerings than seen in the first quarter, and the medical costs of many Medicare Advantage beneficiaries new to UnitedHealthcare remained higher than expected.
The company expects to return to growth in 2026.

Management

UnitedHealth CEO Andrew Witty Steps Down For Personal Reasons; Chair Stephen Hemsley Takes Over As New Chief, Expects To Reurn To Growth In 2026

Honda Motor Co FY25 GAAP EPS ¥178.93 Down From ¥225.88 YoY, Sales ¥21.688T Up From ¥20.428T YoY

First product validated at the VALOR lab's new RF-shielded anechoic chamber
CHANDLER, Ariz., May 13, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4425153-1&amp;h=1206137132&amp;u=https%3A%2F%2Fwww.viavisolutions.com%2F&amp;a=VIAVI+Solutions+Inc.">VIAVI Solutions Inc.</a> (VIAVI) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) today announced that <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4425153-1&amp;h=3385565414&amp;u=https%3A%2F%2Fmetanoia-comm.com%2F&amp;a=Metanoia+Communications+Inc.">Metanoia Communications Inc.</a>'s JURA&nbsp;Open Radio Unit (O-RU) has successfully completed end-to-end over-the-air (OTA) validation at the VIAVI Automated Lab-as-a-Service (VALOR&#x2122;). It is the first product to be validated at the lab's new RF-shielded anechoic chamber to ensure compliance with O-RAN and 3GPP specifications.

VIAV

VIAVI Solutions Says Metanoia Communications' JURA Open Radio Unit Completes End-To-End Over-The-Air Validation At VIAVI Automated Lab-As-A-Service

Large Cap

Health Care

General

UnitedHealth Appoints Stephen Hemsley As Its CEO, Effective Immediately, Following Andrew Witty's Decision To Step Down As CEO For Personal Reasons. Hemsley, Who Served As Company CEO From 2006-2017, Will Remain Chairman Of The Company's Board Of Directors And Witty Will Serve As A Senior Adviser To Hemsley

Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONEK#NASDAQ">UONEK</a>) reported quarterly losses of $(0.26) per share. This is a 273.33 percent decrease over earnings of $0.15 per share from the same period last year. The company reported $92.23 million in sales this quarter. This is a 11.66 percent decrease over sales of $104.41 million the same period last year.

UONEK

Urban One Q1 EPS $(0.26) Down From $0.15 YoY, Sales $92.23M Down From $104.41M YoY

Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.16 by 37.5 percent. This is a 15.38 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $48.31 million which beat the analyst consensus estimate of $47.40 million by 1.92 percent. This is a 3.79 percent increase over sales of $46.55 million the same period last year.

Sotherly Hotels Q1 Adj. FFO $0.22 Beats $0.16 Estimate, Sales $48.31M Beat $47.40M Estimate

Macro Economic Events

Econ #s

INDA

India Consumer Price Index (YoY) For April 3.16% Vs. 3.27% Est.; 3.34% Prior

Eurozone ZEW Economic Sentiment For May 11.6 Vs. -3.5 Est.; -18.5 Prior

Germany ZEW Economic Sentiment For May 25.2 Vs. 10.7 Est.; -14.0 Prior

Germany ZEW Current Conditions For May -82.0 Vs. -77.0 Est.; -81.2 Prior

Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.32 by 40.63 percent. The company reported quarterly sales of $192.35 million which missed the analyst consensus estimate of $198.83 million by 3.26 percent.

FLOC

Flowco Holdings Q1 Adj. EPS $0.45 Beats $0.32 Estimate, Sales $192.35M Miss $198.83M Estimate

Press Releases

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of Shareholders

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HMST, COOP, OPTN, RDFN on Behalf of Shareholders

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - OPTN, SLRN, AKYA, SHYF

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COOP, MESA on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, OPTN, AZEK, MESA on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders

Comments

OptiNose

OptiNose (OPTN) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL